Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of EBITDA Margin data on record, last reported at 91114.39% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2092311.0% year-over-year to 91114.39%; the TTM value through Dec 2025 reached 482.92%, up 8901940.0%, while the annual FY2025 figure was 482.92%, 8901940.0% up from the prior year.
  • EBITDA Margin reached 91114.39% in Q4 2025 per VRDN's latest filing, down from 48.61% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 48.61% in Q3 2025 and bottomed at 134548.0% in Q2 2025.
  • Average EBITDA Margin over 5 years is 55060.07%, with a median of 67220.83% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: crashed -6489961bps in 2023, then surged 8740953bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 13598.13% in 2021, then tumbled by -217bps to 43080.95% in 2022, then tumbled by -114bps to 92302.78% in 2023, then dropped by -21bps to 112037.5% in 2024, then increased by 19bps to 91114.39% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 91114.39% in Q4 2025, 48.61% in Q3 2025, and 134548.0% in Q2 2025.